PMID- 36057010
OWN - NLM
STAT- MEDLINE
DCOM- 20221205
LR  - 20230904
IS  - 2008-2231 (Electronic)
IS  - 1560-8115 (Print)
IS  - 1560-8115 (Linking)
VI  - 30
IP  - 2
DP  - 2022 Dec
TI  - Efficacy and safety of ibrutinib in mantle cell lymphoma: A systematic review and 
      meta-analysis.
PG  - 367-378
LID - 10.1007/s40199-022-00444-w [doi]
AB  - OBJECTIVES: Since the US Food and Drug Administration (FDA) approved ibrutinib to 
      treat patients with refractory/relapsed mantle cell lymphoma (R/R MCL), it is 
      used in clinical trials, whether as a single agent or in combination with other 
      chemotherapy agents. The efficacy and safety of ibrutinib administration alone or 
      in combinations have not been studied systematically. This study systematically 
      reviewed the efficacy and safety of ibrutinib-containing regimens for the 
      treatment of patients with MCL. EVIDENCE ACQUISITION: We performed a systematic 
      search in PubMed, Cochrane CENTRAL, Embase, Web of Science, and Scopus. Then, a 
      team of independent reviewers selected relevant studies and extracted the data. 
      RESULTS: From a total of 1,436 studies, 12 trials were eligible. The overall 
      response rates (ORRs) of patients with R/R MCL receiving single-agent ibrutinib 
      ranged between 62.7% to 93.8%, and the ORRs of ibrutinib combinations ranged from 
      74 to 88%. In patients with newly diagnosed MCL receiving ibrutinib and 
      rituximab, ORR ranged from 84 to 100%. The highest progression-free survival 
      (PFS) was reported in patients receiving ibrutinib and rituximab (43 months). The 
      meta-analysis performed on adverse events (AEs) demonstrated that single-agent 
      ibrutinib had a high risk of bleeding, nausea, and diarrhea. CONCLUSION: 
      Single-agent ibrutinib showed acceptable efficacy and safety in the treatment of 
      patients with MCL. Moreover, combining ibrutinib with other agents such as 
      rituximab, venetoclax, and ublituximab can increase its efficacy and reduce 
      chemotherapy-induced resistance in most cases; however, in the case of 
      combination therapy, patients need to be monitored more strictly in terms of AEs. 
      In our review, the ibrutinib and rituximab combination showed promising results 
      in patients with R/R MCL. Also, this combination showed favorable efficacy and 
      safety in patients with newly diagnosed untreated MCL, making it a great 
      candidate to be studied more in large and well-designed trials.
CI  - (c) 2022. The Author(s), under exclusive licence to Tehran University of Medical 
      Sciences.
FAU - Roufarshbaf, Mohammad
AU  - Roufarshbaf M
AUID- ORCID: 0000-0002-7146-4166
AD  - Student Research Committee, Faculty of Pharmacy, Isfahan University of Medical 
      Sciences, Isfahan, Iran.
FAU - Javeri, Mohsen
AU  - Javeri M
AD  - Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, 
      Isfahan University of Medical Sciences, Isfahan, Iran.
FAU - Akbari, Vajihe
AU  - Akbari V
AD  - Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Isfahan 
      University of Medical Sciences, Isfahan, Iran.
FAU - Matin, Payman Hosseini
AU  - Matin PH
AD  - Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, 
      Isfahan University of Medical Sciences, Isfahan, Iran.
FAU - Farrokhi, Pegah
AU  - Farrokhi P
AD  - Department of Pharmacy Practice and Pharmaceutical Sciences, College of Pharmacy, 
      University of Minnesota, Minneapolis, MN, United States.
FAU - Sadeghi, Erfan
AU  - Sadeghi E
AD  - Research Consultation Center (RCC), Shiraz University of Medical Sciences, 
      Shiraz, Iran.
FAU - Heidari, Zahra
AU  - Heidari Z
AD  - Department of Epidemiology and Biostatistics, Faculty of Health, Isfahan 
      University of Medical Sciences, Isfahan, Iran.
FAU - Moghaddas, Azadeh
AU  - Moghaddas A
AUID- ORCID: 0000-0003-0412-6172
AD  - Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, 
      Isfahan University of Medical Sciences, Isfahan, Iran. moghaddas@pharm.mui.ac.ir.
LA  - eng
GR  - 399176/Isfahan University of Medical Sciences/
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20220903
PL  - Switzerland
TA  - Daru
JT  - Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences
JID - 101125969
RN  - 1X70OSD4VX (ibrutinib)
RN  - 4F4X42SYQ6 (Rituximab)
RN  - 0 (Pyrimidines)
RN  - 0 (Pyrazoles)
SB  - IM
MH  - Adult
MH  - Humans
MH  - *Lymphoma, Mantle-Cell/drug therapy/pathology
MH  - Rituximab/therapeutic use
MH  - Pyrimidines/adverse effects
MH  - Pyrazoles/adverse effects
PMC - PMC9715897
OTO - NOTNLM
OT  - Adverse events
OT  - Efficacy
OT  - Ibrutinib
OT  - Mantle cell lymphoma
OT  - Survival
COIS- The authors declare that they have no competing interests.
EDAT- 2022/09/04 06:00
MHDA- 2022/12/06 06:00
PMCR- 2023/09/03
CRDT- 2022/09/03 11:16
PHST- 2021/10/21 00:00 [received]
PHST- 2022/05/25 00:00 [accepted]
PHST- 2022/09/04 06:00 [pubmed]
PHST- 2022/12/06 06:00 [medline]
PHST- 2022/09/03 11:16 [entrez]
PHST- 2023/09/03 00:00 [pmc-release]
AID - 10.1007/s40199-022-00444-w [pii]
AID - 444 [pii]
AID - 10.1007/s40199-022-00444-w [doi]
PST - ppublish
SO  - Daru. 2022 Dec;30(2):367-378. doi: 10.1007/s40199-022-00444-w. Epub 2022 Sep 3.